TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24139461

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 21389855

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg) and vitamin B12 (0.4 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vitamin B6 (40 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18312874

Group type: EXPERIMENTAL
Intervention: Ellman generator
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Select Sutter generator
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Coblator generator
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Somnus generator
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment (all generators)
Number of subjects: 120
Study: 16710710

Group type: EXPERIMENTAL
Intervention: Multidisciplinary job retention vocational rehabilitation programme
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual outpatient care
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Complete sick leave
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Depression score of the hospital anxiety and depression scale
Number of subjects: 112
Study: 14748999

Group type: EXPERIMENTAL
Intervention: Leflunomide plus methotrexate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methotrexate only (Control)
Number of subjects: 40
Study: 10945508

Group type: EXPERIMENTAL
Intervention: Cefdinir 100 mg BID
Number of subjects: 661

Group type: COMPARATOR
Intervention: Cefaclor 250 mg TID
Number of subjects: 661
Study: 8973979

Group type: EXPERIMENTAL
Intervention: Exercise (continuous incremental cycling protocol at 55%, 70%, and 85% VO2peak)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: ConA (1.25 micrograms/ml, 2.5 micrograms/ml, and 5.0 micrograms/ml)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Exercise (incremental workload)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Resting and exercise conditions
Number of subjects: 64
Study: 1478135

Group type: EXPERIMENTAL
Intervention: Active music therapy provided every day for 8 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Antidepressive drugs (same for both groups)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combined treatment (active music therapy + antidepressive drugs)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Active music therapy
Number of subjects: 68
Study: 6420374

Group type: EXPERIMENTAL
Intervention: 1-2 units insulin/kg body weight/24 h with feed
Number of subjects: 10

Group type: COMPARATOR
Intervention: Feed only (no insulin)
Number of subjects: 10
Study: 31674267

Group type: EXPERIMENTAL
Intervention: SLE responder index achievement
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: New SELENA-SLEDAI flare index flare
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Changes in BILAG (constitutional)
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Changes in BILAG (musculoskeletal and hematological)
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: SLE responder index attainment
Number of subjects: 867
Study: 30086681

Group type: EXPERIMENTAL
Intervention: Erenumab 70mg
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Erenumab 140mg
Number of subjects: 955

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 955
Study: 26562292

Group type: EXPERIMENTAL
Intervention: Risk model-guided (RMG) antiemetic prophylaxis
Number of subjects: 324

Group type: COMPARATOR
Intervention: Physician's choice (PC) antiemetic therapy
Number of subjects: 324
Study: 24375082

Group type: EXPERIMENTAL
Intervention: Boiled camel milk (CM) for group I (n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Raw camel milk (CM) for group II (n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (cow milk) for group III (n = 15)
Number of subjects: 45
Study: 22282552

Group type: EXPERIMENTAL
Intervention: Zephyr® EBV treatment
Number of subjects: 171

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 171
Study: 20633443

Group type: EXPERIMENTAL
Intervention: Interactive rTMS (individual stimuli based on background EEG activity)
Number of subjects: 44
Study: 18331610

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 20
Study: 15760403

Group type: EXPERIMENTAL
Intervention: Doxorubicin chemotherapy (15 mg/m2 biweekly pre-operatively, single dose intra-operatively, total dosage of 300 mg/m2 post-operatively)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (transplanted only, no chemotherapy)
Number of subjects: 62
Study: 11704184

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 5
Study: 9669632

Group type: EXPERIMENTAL
Intervention: Cisapride, 5 mg three times daily (n = 19)
Number of subjects: 38
Study: 8308962

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 200
Study: 2926468

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 5-FU administered 24 hours a day for a protracted time (10 weeks or more)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Daily bolus dose of 5-FU administered intravenously for five consecutive days and repeated at 5-week intervals
Number of subjects: 179

Group type: COMPARATOR
Intervention: Bolus arm
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Infusional arm
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 179
Study: 31563919

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided technique
Number of subjects: 66

Group type: COMPARATOR
Intervention: Palpation technique
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 66
Study: 28000941

Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sigmoid resection
Number of subjects: 88
Study: 26209642

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control (not specified, but implied as the alternative treatment)
Number of subjects: 218
Study: 22552597

Group type: EXPERIMENTAL
Intervention: Verbal instruction by leaflet
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Verbal instruction supported by demonstration
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control, no instruction
Number of subjects: 98
Study: 22256472

Group type: EXPERIMENTAL
Intervention: Stanol-containing soymilk (2g)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (regular soymilk)
Number of subjects: 120
Study: 19139031

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (Diane(35)Diario) - 35 microg ethinyl-estradiol plus 2 mg cyproterone acetate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metformin - 850 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (non-hyperandrogenic women)
Number of subjects: 40
Study: 17713165

Group type: EXPERIMENTAL
Intervention: Simultaneous peginterferon alpha-2b and lamivudine (group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lamivudine started eight weeks before peginterferon (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lamivudine started eight weeks after peginterferon (group 3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups at week 104
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: At 24 weeks post-treatment
Number of subjects: 30
Study: 15126801

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg once daily
Number of subjects: 103

Group type: COMPARATOR
Intervention: Medical castration with a luteinizing hormone releasing hormone analogue
Number of subjects: 103
Study: 11472703

Group type: EXPERIMENTAL
Intervention: Self-expanding stents (SE)
Number of subjects: 1096
Study: 9511837

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (Fuji III; GIC)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Light-cured resin-based fissure sealant (Delton; LCR)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Comparison of GIC to LCR
Number of subjects: 166
Study: 8295585

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine therapy
Number of subjects: 1500
Study: 2926945

Group type: EXPERIMENTAL
Intervention: Workshop group (received free patient education materials and a 6-hour training workshop)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Materials group (received free patient education materials)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No-assistance group (received nothing)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Patients asked if they smoked
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Patients who were asked if they smoked
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Patients who were not asked if they smoked
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: All groups of physicians
Number of subjects: 66
Study: 29650363

Group type: EXPERIMENTAL
Intervention: Chemotherapy (3 preoperative cycles and 3 postoperative cycles of intravenous epirubicin, cisplatin or oxaliplatin, and capecitabine)
Number of subjects: 788

Group type: COMPARATOR
Intervention: Chemoradiotherapy (preoperative chemotherapy followed by 45 Gy in 25 fractions of radiotherapy combined with capecitabine and cisplatin)
Number of subjects: 788
Study: 28836960

Group type: EXPERIMENTAL
Intervention: Five weekly sessions of psychosocial intervention combined with early palliative care (Arm A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Early palliative care only (Arm B)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard cancer treatment (Arm C)
Number of subjects: 63
Study: 25454930

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (CPAP) at three different levels
Number of subjects: 0
Study: 23915698

Group type: EXPERIMENTAL
Intervention: Self-management intervention for adolescents with schizophrenia and their families
Number of subjects: 0
Study: 21967361

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous lorazepam
Number of subjects: 0
Study: 19187375

Group type: EXPERIMENTAL
Intervention: Abnormal uterine artery Doppler
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Abnormal umbilical artery Doppler
Number of subjects: 353

Group type: COMPARATOR
Intervention: Normal umbilical artery Doppler
Number of subjects: 353
Study: 16457967

Group type: EXPERIMENTAL
Intervention: Attendance at skin cancer clinics
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Reasons for attendance
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Reasons for non-attendance
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Future participation plans
Number of subjects: 1041
Study: 14977907

Group type: EXPERIMENTAL
Intervention: Formula A (DHA supplemented formula)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Formula B (DHA unsupplemented formula)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (human milk)
Number of subjects: 54
Study: 11157146

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) followed by mycophenolate mofetil (MMF)
Number of subjects: 13
Study: 8893143

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Niferex (polysaccharide ferric complex)
Number of subjects: 12
Study: 2323085

Group type: EXPERIMENTAL
Intervention: Topical antibiotic (gentamicin sulphate)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Topical antiseptic (aluminium acetate)
Number of subjects: 139
Study: 223950

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid therapy for 5 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid therapy for 10 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid therapy for 15 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid therapy
Number of subjects: 21
Study: 31626696

Group type: COMPARATOR
Intervention: Phentermine HCl 60 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pitolisant 35.6 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pitolisant 213.6 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31522078

Group type: EXPERIMENTAL
Intervention: Below-knee compression garment (BK)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Above-knee compression garment (AK)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Whole-knee compression garment (WK)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study: 28277845

Group type: EXPERIMENTAL
Intervention: New mometasone furoate cream
Number of subjects: 162

Group type: COMPARATOR
Intervention: Positive control (marketed Elocon cream)
Number of subjects: 162
Study: 25586724

Group type: EXPERIMENTAL
Intervention: sugammadex 1.0 mg kg(‐1)
Number of subjects: 300

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 300
Study: 25222806

Group type: EXPERIMENTAL
Intervention: rhBSSL treatment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 22751847

Group type: EXPERIMENTAL
Intervention: Fingolimod, 0.5 mg
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Fingolimod, 1.25 mg
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Fingolimod (both doses)
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1272
Study: 21375019

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 30 min, once daily for 4 weeks.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mecobalamine (500 microg) intramuscular injection, once daily for 4 weeks.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mecobalamine treatment
Number of subjects: 80
Study: 17699944

Group type: COMPARATOR
Intervention: Intravenous dexamethasone 200 mg once daily for three days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 250 mg/six-hourly for three days followed by oral prednisolone for 11 days
Number of subjects: 21
Study: 16045572

Group type: EXPERIMENTAL
Intervention: Ultraflex expandable stent
Number of subjects: 65

Group type: COMPARATOR
Intervention: High-dose-rate endoluminal brachytherapy (7 Gy x 3 given in 2-4 weeks)
Number of subjects: 65
Study: 12163429

Group type: EXPERIMENTAL
Intervention: Intracoronary brachytherapy
Number of subjects: 252

Group type: COMPARATOR
Intervention: Standard therapy (placebo)
Number of subjects: 252
Study: 10429771

Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron orally 45‐60 minutes before anaesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2.5 mg i.v. DHB + placebo p.o. (positive control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron orally 45‐60 minutes before anaesthesia and 2.5 mg i.v. DHB during anaesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo tablet administered 45‐60 minutes before anaesthesia (negative control group)
Number of subjects: 80
Study: 8680536

Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily for 6 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Double-therapy (300 mg amoxicillin granules and 250 mg metronidazole thrice daily for 2 weeks + cimetidine)
Number of subjects: 50
Study: 1299500

Group type: EXPERIMENTAL
Intervention: Protein supplementation (PRO)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Wingate test (WIN)
Number of subjects: 11
Study: 6432001

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Niludipine (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (chronic administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Niludipine (chronic administration)
Number of subjects: 0
Study: 30885134

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (2 mg/kg bolus followed by 1.5 mg/kg/h infusion)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (0.5 μg/kg bolus followed by 0.4 μg/kg/h infusion)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 120
Study: 28864244

Group type: EXPERIMENTAL
Intervention: High quadriceps activation battery (≥4/6)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Low quadriceps activation battery (≤3/6)
Number of subjects: 162
Study: 27651882

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) plus amniotic membrane (AM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF) with connective tissue graft (CTG)
Number of subjects: 11
Study: 24477319

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of parathyroid hormone (PTH) for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual treatment (standard care)
Number of subjects: 0
Study: 22449836

Group type: EXPERIMENTAL
Intervention: Ethnically-targeted statement in direct mail letters
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Personalized letters
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Direct mail letters for minority women
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Direct mail letters
Number of subjects: 30000
Study: 19123156

Group type: EXPERIMENTAL
Intervention: Oral supplementation with EPA (720 mg/day) and DHA (480 mg/day) for 6 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (16 patients)
Number of subjects: 38
Study: 17242426

Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.2 mg/kg daily for 3 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15970715

Group type: EXPERIMENTAL
Intervention: High dose heparin (600 U/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low dose heparin (300 U/kg)
Number of subjects: 40
Study: 12021557

Group type: EXPERIMENTAL
Intervention: Trauma-writing group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 26
Study: 9728773

Group type: EXPERIMENTAL
Intervention: Diagnostic pure-tone audiometry in a typical practice setting
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standardized audiological setting
Number of subjects: 119
Study: 7895538

Group type: EXPERIMENTAL
Intervention: Pure fat meal (25 g triglycerides)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Mixed meal (8 g fat, 10 g protein, 32 g dextrose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fat-free meal (25 g albumin, 32 g dextrose)
Number of subjects: 6
Study: 2403903

Group type: EXPERIMENTAL
Intervention: Iodinated glycerol (Organidin), 60 mg qid
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study: 79028

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiography (E.R.C.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous cholangiography (I.V.C.)
Number of subjects: 0
Study: 31795799

Group type: EXPERIMENTAL
Intervention: Psychological care
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no psychological care)
Number of subjects: 42
Study: 31446464

Group type: EXPERIMENTAL
Intervention: New two-thumb technique (nTTT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Knocking-fingers technique (KF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Two-thumb-encircling hand techniques (TTHT)
Number of subjects: 10
Study: 27515478

Group type: EXPERIMENTAL
Intervention: MAL-PDT (methyl aminolevulinate photodynamic therapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: pPDT (placebo photodynamic therapy)
Number of subjects: 40
Study: 26077585

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration using various aspiration catheters (Eliminate, Export, Pronto)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombus aspiration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug-eluting stents with thrombus aspiration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postdilation with thrombus aspiration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombus aspiration and percutaneous coronary intervention
Number of subjects: 0
Study: 23582934

Group type: EXPERIMENTAL
Intervention: levothyroxine+iron salt
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: levothyroxine+placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: iron salt+placebo
Number of subjects: 60
Study: 21671745

Group type: EXPERIMENTAL
Intervention: Points of unpredictability in the movie where prediction was more difficult.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased activity in midbrain and striatal regions associated with dopamine release.
Number of subjects: 0
Study: 19637397

Group type: COMPARATOR
Intervention: Donepezil (5 mg)
Number of subjects: 0
Study: 16563810

Group type: EXPERIMENTAL
Intervention: Conservative treatment with additional brace treatment
Number of subjects: 117

Group type: COMPARATOR
Intervention: Conservative treatment alone
Number of subjects: 117
Study: 15283826

Group type: EXPERIMENTAL
Intervention: Dexamethasone (50, 100, 150 microg x kg(‐1), maximum dose 8 mg) with ondansetron (50 microg x kg(‐1))
Number of subjects: 102

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 102
Study: 11739137

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1000 microg/d (stepdown approach)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone propionate 200 microg/d (constant dose approach)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (both approaches)
Number of subjects: 0
Study: 9234035

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 195

Group type: COMPARATOR
Intervention: No alcohol consumption (control)
Number of subjects: 195
Study: 8424427

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid alpha-interferon (L-IFN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 40
Study: 3687269

Group type: EXPERIMENTAL
Intervention: Mesenteric anaesthesia according to Finsterer
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anaesthesia without mesenteric anaesthesia
Number of subjects: 50
Study: 28735368

Group type: EXPERIMENTAL
Intervention: MDMA (75 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ketanserin (40 mg) as pre-treatment
Number of subjects: 20
Study: 27113325

Group type: EXPERIMENTAL
Intervention: Static stretching (SS) intervention for the hamstrings of their dominant leg for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30